Insider Selling: Glaukos (NYSE:GKOS) Director Sells $703,800.00 in Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Glaukos Price Performance

NYSE GKOS opened at $143.82 on Thursday. The stock has a market capitalization of $8.45 billion, a price-to-earnings ratio of -43.85 and a beta of 0.94. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $148.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. The business’s fifty day moving average price is $119.11 and its 200-day moving average price is $112.93.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. Glaukos’s revenue was up 41.2% compared to the same quarter last year. On average, equities analysts predict that Glaukos Corporation will post -0.57 earnings per share for the current year.

Institutional Investors Weigh In On Glaukos

Institutional investors have recently bought and sold shares of the business. Wealth Alliance LLC boosted its stake in shares of Glaukos by 4.5% in the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock worth $247,000 after acquiring an additional 98 shares during the period. Smartleaf Asset Management LLC raised its stake in Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after purchasing an additional 122 shares during the period. Larson Financial Group LLC raised its stake in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the period. CWM LLC lifted its holdings in Glaukos by 25.2% in the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 143 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in Glaukos by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock worth $947,000 after purchasing an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on GKOS shares. Needham & Company LLC upped their price target on shares of Glaukos from $127.00 to $136.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Wells Fargo & Company raised their price objective on shares of Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Citigroup boosted their target price on shares of Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Stifel Nicolaus set a $170.00 target price on shares of Glaukos in a report on Thursday, April 30th. Finally, William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $144.42.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.